FENNEC PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 of 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Fennec Pharmaceuticals Inc.
| By: | /s/ Rostislav Raykov |
|---|---|
| Rostislav Raykov | |
| Chief Executive Officer and Director | |
| Date: March 29, 2024 | |
We, the undersigned directors and officers of Fennec Pharmaceuticals Inc., do hereby constitute and appoint Rostislav Raykov, as our true and lawful attorney-in-fact and agent with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which such attorney-in-fact and agent may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form 10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto; and we do hereby ratify and confirm all that said attorney-in-fact and agent, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ Rostislav Raykov | Chief Executive Officer | March 29, 2024 |
| Rostislav Raykov | (principal executive officer) and Director | |
| /s/ Robert Andrade | Chief Financial Officer | March 29, 2024 |
| Robert Andrade | (principal financial officer and principalaccounting officer) | |
| /s/ Adrian J. Haigh | Chief Operating Officer | March 29, 2024 |
| Adrian J. Haigh | (principal operations office) | |
| /s/ Dr. Khalid Islam | Director | March 29, 2024 |
| Dr. Khalid Islam | ||
| /s/ Chris A. Rallis | Director | March 29, 2024 |
| Chris A. Rallis | ||
| /s/ Marco Brughera | Director | March 29, 2024 |
| Marco Brughera | ||
| /s/ Jodi Cook | Director | March 29, 2024 |
| Jodi Cook | ||
FENNEC PHARMACEUTICALS INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 | |
|---|---|---|
| | | |
| Consolidated Balance Sheets | | F-4 |
| | | |
| Consolidated Statements of Operations | | F-5 |
| | | |
| Consolidated Statements of Shareholders’ Deficit | | F-6 |
| | | |
| Consolidated Statements of Cash Flows | | F-7 |
| | | |
| Notes to the Consolidated Financial Statements | | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.